Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Top Cited Papers
- 1 August 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (15) , 3477-3482
- https://doi.org/10.1200/jco.2001.19.15.3477
Abstract
PURPOSE: The present study attempted to identify characteristics that correlated with clinical response to interleukin (IL)-2 therapy in patients with metastatic melanoma. PATIENTS AND METHODS: We ...Keywords
This publication has 26 references indexed in Scilit:
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Vitiligo in Patients with MelanomaJournal of Immunotherapy, 1996
- Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin-2 AloneJournal of Immunotherapy, 1995
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- Repetitive Weekly Cycles of 4-Day Continuous Infusion of Recombinant Interleukin-2: A Phase I StudyJournal of Immunotherapy, 1992
- Vitiligo and Cutaneous MelanomaDermatology, 1991
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983